A biopharmaceutical company focused on the development and commercialization of products designed to treat respiratory, inflammatory and critical care diseases linked to the body's inflammatory response.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Expect major revenue increases starting 2H07 due to increase of effective salesforce from 20 to 240 with Dey partnership and new reformulation of zileuton (ZyFlo CR). May see some earlier rev. uptick due to co-marketing started in Q2. New formulation is a feasible alternative advantage to Singulair, which some people are reporting, produces side effects such as depression, anxiety.